Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 62.1 TWD 0.16% Market Closed
Market Cap: 10.2B TWD
Have any thoughts about
Tanvex BioPharma Inc?
Write Note

Gross Margin
Tanvex BioPharma Inc

26.5%
Current
9%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
26.5%
=
Gross Profit
10.9m
/
Revenue
41m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
KY
Tanvex BioPharma Inc
TWSE:6541
10.2B TWD
26%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
314.6B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
117.3B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
136.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36.2B EUR
89%
Country KY
Market Cap 10.2B TWD
Gross Margin
26%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 314.6B USD
Gross Margin
67%
Country US
Market Cap 141.2B USD
Gross Margin
60%
Country US
Market Cap 117.3B USD
Gross Margin
78%
Country US
Market Cap 105.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 136.4B AUD
Gross Margin
52%
Country US
Market Cap 78.4B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36.2B EUR
Gross Margin
89%
No Stocks Found

Tanvex BioPharma Inc
Glance View

Market Cap
10.2B TWD
Industry
Biotechnology

Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.

Intrinsic Value
1.89 TWD
Overvaluation 97%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
26.5%
=
Gross Profit
10.9m
/
Revenue
41m
What is the Gross Margin of Tanvex BioPharma Inc?

Based on Tanvex BioPharma Inc's most recent financial statements, the company has Gross Margin of 26.5%.